OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10381478" target="_blank" >RIV/00216208:11140/18:10381478 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/18:10381478
Výsledek na webu
<a href="https://doi.org/10.21873/anticanres.12806" target="_blank" >https://doi.org/10.21873/anticanres.12806</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.12806" target="_blank" >10.21873/anticanres.12806</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma
Popis výsledku v původním jazyce
BACKGROUND/AIM: Melanoma represents one of the most aggressive forms of cancer. With the rapid increases in the incidence of melanoma in the United States, Australia and Europe over the last decades, melanoma has been considered an epidemic cancer in these areas. The aim of our study was to evaluate the utility of osteoprotegerin (OPG), osteopontin (OPN), epidermal growth factor (EGF) and vascular endothelial growth factor VEGF for the diagnosis and prognosis of melanoma. PATIENTS AND METHODS: Overall, 322 individuals were assessed: 183 melanoma patients and 139 healthy individuals. Melanoma patients were divided into four subgroups according to the Breslow score. OPN, OPG, EGF, and VEGF were determined in each plasma sample. RESULTS: The serum levels of the following biomarkers were statistically significantly higher in the melanoma group compared to the control group: OPG and, OPN (p<0.0001), EGF (p=0.0379). In the first stage, OPG (p=0.0236) and OPN (p=0.0327) showed a statistically significant increase. Concerning positive and negative sentinel node metastases a statistically significant change was observed in: OPN (p<0.0001), EGF (p=0.0114), VEGF (p=0.0114). CONCLUSION: OPG and OPN are promising biomarkers of early-stage melanoma. EGF and VEGF appear to be prognostic biomarkers. Copyright(C) 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Název v anglickém jazyce
OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma
Popis výsledku anglicky
BACKGROUND/AIM: Melanoma represents one of the most aggressive forms of cancer. With the rapid increases in the incidence of melanoma in the United States, Australia and Europe over the last decades, melanoma has been considered an epidemic cancer in these areas. The aim of our study was to evaluate the utility of osteoprotegerin (OPG), osteopontin (OPN), epidermal growth factor (EGF) and vascular endothelial growth factor VEGF for the diagnosis and prognosis of melanoma. PATIENTS AND METHODS: Overall, 322 individuals were assessed: 183 melanoma patients and 139 healthy individuals. Melanoma patients were divided into four subgroups according to the Breslow score. OPN, OPG, EGF, and VEGF were determined in each plasma sample. RESULTS: The serum levels of the following biomarkers were statistically significantly higher in the melanoma group compared to the control group: OPG and, OPN (p<0.0001), EGF (p=0.0379). In the first stage, OPG (p=0.0236) and OPN (p=0.0327) showed a statistically significant increase. Concerning positive and negative sentinel node metastases a statistically significant change was observed in: OPN (p<0.0001), EGF (p=0.0114), VEGF (p=0.0114). CONCLUSION: OPG and OPN are promising biomarkers of early-stage melanoma. EGF and VEGF appear to be prognostic biomarkers. Copyright(C) 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Svazek periodika
38
Číslo periodika v rámci svazku
8
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
5
Strana od-do
4907-4911
Kód UT WoS článku
000449948300066
EID výsledku v databázi Scopus
2-s2.0-85050807886